1. Nutting C, Dearnaley DP, Webb S. Intensity modulated radiation therapy: a clinical review. Br J Radiol. 2000; 73(869):459–469. PMID:
10884741.
2. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166(3):876–881. PMID:
11490237.
3. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004; 58(3):682–687. PMID:
14967420.
4. Barnett GC, Wilkinson J, Moody AM, Wilson CB, Sharma R, Klager S, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol. 2009; 92(1):34–41. PMID:
19375808.
5. Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007; 82(3):254–264. PMID:
17224195.
6. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007; 25(31):4873–4879. PMID:
17971582.
7. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2):127–136. PMID:
21236730.
8. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008; 26(13):2085–2092. PMID:
18285602.
9. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006; 66(4):981–991. PMID:
17145528.
10. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47(2):127–141. PMID:
25761484.
11. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci. 2010; 25(8):1113–1121. PMID:
20676319.
12. Kang JK, Kim MS, Jang WI, Seo YS, Kim HJ, Cho CK, et al. The clinical utilization of radiation therapy in Korea between 2009 and 2013. Radiat Oncol J. 2016; 34(2):88–95. PMID:
27381419.
13. Kang JK, Kim MS, Jang WI, Kim HJ, Cho CK, Yoo HJ, et al. The clinical status of radiation therapy in Korea in 2009 and 2013. Cancer Res Treat. 2016; 48(3):892–898. PMID:
26693912.
14. Ji YH, Jung H, Yang K, Cho CK, Yoo SY, Yoo HJ, et al. Trends for the past 10 years and international comparisons of the structure of Korean radiation oncology. Jpn J Clin Oncol. 2010; 40(5):470–475. PMID:
20139270.
15. Huh SJ. Korean Society of Therapeutic Radiology and Oncology (KOSTRO). Current status of the infrastructure and characteristics of radiation oncology in Korea. Jpn J Clin Oncol. 2007; 37(8):623–627. PMID:
17673472.
17. Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009; 24(1):63–71. PMID:
19004861.
18. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011; 43(1):1–11. PMID:
21509157.
19. Korean Statistical Information Service (KOSIS). Updated 2017. Accessed June 2017.
http://kosis.kr.
20. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001; 51(4):880–914. PMID:
11704310.
21. Shen X, Showalter TN, Mishra MV, Barth S, Rao V, Levin D, et al. Radiation oncology services in the modern era: evolving patterns of usage and payments in the office setting for medicare patients from 2000 to 2010. J Oncol Pract. 2014; 10(4):e201–e207. PMID:
24756145.
22. Young R, Snyder B. IMRT (intensity modulated radiation therapy): progress in technology and reimbursement. Radiol Manage. 2001; 23(6):20–26. PMID:
11793560.
23. Dunlop S, Coyte PC, McIsaac W. Socio-economic status and the utilisation of physicians’ services: results from the Canadian National Population Health Survey. Soc Sci Med. 2000; 51(1):123–133. PMID:
10817475.
24. Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, et al. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Int J Radiat Oncol Biol Phys. 2005; 61(2):400–408. PMID:
15667959.
25. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. Cancer. 2003; 98(1):204–211. PMID:
12833473.
26. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005; 104(6):1296–1303. PMID:
16078260.
27. Jefferies S, Taylor A, Reznek R. Radiotherapy Planning Working Party. Results of a national survey of radiotherapy planning and delivery in the UK in 2007. Clin Oncol (R Coll Radiol). 2009; 21(3):204–217. PMID:
19250811.
28. Mayles WP. Radiotherapy Development Board. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol (R Coll Radiol). 2010; 22(8):636–642. PMID:
20667700.
29. AlDuhaiby EZ, Breen S, Bissonnette JP, Sharpe M, Mayhew L, Tyldesley S, et al. A national survey of the availability of intensity-modulated radiation therapy and stereotactic radiosurgery in Canada. Radiat Oncol. 2012; 7(1):18. PMID:
22309806.